Atlas Trials

Bioequivalence Study for Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers

Clinical trial NCT05982990 · UNKNOWN

Trial details

NCT number
NCT05982990
Sponsor
Respirent Pharmaceuticals Co Ltd.
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Bioequivalence
Start date
2023-08-01
Primary completion
2023-09-01
Enrollment
34

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.